euro adhoc: LION bioscience AG / Strategic management decisions / LION bioscience sells bioinformatics business, Dr. Thure Etzold resigns as CEO

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

04.04.2006

Ad-hoc Release

LION bioscience sells bioinformatics business
Dr. Thure Etzold resigns as CEO

Heidelberg, April 4, 2006 - LION bioscience AG today announced the
successful completion of the sales process regarding its
bioinformatics business.

As of April 4, 2006 the bioinformatics business, consisting of the
subsidiaries LION Bioscience Ltd, Cambridge UK and LBAV Inc.,
Cambridge, MA, USA is transferred to BioWisdom Ltd., Cambridge,
UK. The sales price is up to 4 Mio E.

In this context, Dr. Thure Etzold, original inventor of the SRS
technology and current CEO of LION, will resign from the LION board
as of April 4, 2006 as planned.

For further information, please contact:

|Peter Willinger |
|Chief Financial Officer |
|Tel: +49 (0) 6221-4038 293 |
|Email: |
|peter.willinger@lionbioscience.com |
###

Except for the historical information contained herein, the matters
set forth in this press release are forward looking. These
forward-looking statements may include projections, assumptions,
estimates, targets, and descriptions of future events. Such
statements are based on currently available information and on
LION's current expectations as to future events that may not prove
to be accurate. These statements are not guarantees of future
performance and involve risks and uncertainties that are difficult
to predict. Many factors could cause the actual results,
performance or achievements of LION to be materially different
from those that may be projected, expected, targeted, expressed
or implied by such statements. All roll-out plans and future dates
with respect to completion of development and market release of LION
products are target dates only based on the company's current
planning and may change in the future. Any delays in the current
product release schedule will have a materially adverse effect on
the company's targets for fiscal year. ###

end of announcement euro adhoc 04.04.2006 15:11:53
--------------------------------------------------------------------------------

ots Originaltext: Lion Bioscience
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Stephan Trautvetter
Director Finance & Accounting
Telefon: +49(0)6221 4038 476
E-Mail: stephan.trautvetter@lionbioscience.com

Branche: Biotechnology
ISIN: DE0005043509
WKN: 504350
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing/prime
standard
New York / ADR
Börse Berlin-Bremen / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade